UBS resumed coverage of Pacs Group (PACS) with a Buy rating with a price target of $42, down from $50. Pacs is well-positioned to take advantage of industry tailwinds that include an aging U.S. population, shifts to lower cost site of care settings, and a fragmented industry that provides ample acquisition opportunities of low performing facilities, the analyst tells investors in a research note. The current valuation reflects a few outstanding regulatory and legal issues and fundamentals are holding strong, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACS:
- Pacs Group reinstated with an Overweight at JPMorgan
- Buy Recommendation for PACS Group Inc.: Strategic Expansion in Skilled Nursing Facilities with Strong Growth Potential
- Pacs Group price target raised to $40 from $32 at Truist
- Pacs Group management to meet with Truist
- Pacs Group names Kelly Priegnitz chief compliance officer